• Angelo Maria Patti, Khalid Al-Rasadi, Rosaria Vincenza Giglio, Dragana Nikolic, Carlo Mannina, Giuseppa Castellino, Roberta Chianetta, Maciej Banach, CiceroArrigo F GAFGDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Giuseppe Lippi, Giuseppe Montalto, Manfredi Rizzo, and Peter P Toth.
• Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Italy.
• Arch Med Sci. 2018 Mar 1; 14 (2): 422441422-441.

AbstractMetabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the beneficial effects of nutraceuticals in patients with MetS, including product standardization, duration of supplementation and definition of optimal dosing, could help better define appropriate treatment. This review focuses on widely marketed nutraceuticals (namely polyphenols, omega-3 fatty acids, macroelements and vitamins) with clinically demonstrated effects on more than one component of MetS.

7 keywords...

hide…